Table 1.
Characteristics at baseline of the study participants
|
All subjects |
Anti-Tat Ab-positive
a
|
Anti-Tat Ab-negative |
|
|---|---|---|---|
| ( n = 61) | ( n = 20) | ( n = 41) | |
| Age (years) |
38 (32–42) |
38 (32–43) |
38 (32–41) |
| Male (%) |
90.2 |
95.0 |
87.8 |
| Female (%) |
9.8 |
5.0 |
12.2 |
| CD4+ (cells/μl) |
544 (463–678) |
546 (500–702) |
541 (454–640) |
| CD4+ (%) |
29.0 (25.0-34.0) |
29.0 (25.0-33.0) |
28.5 (25.5-34.5) |
| Viral load (log10 copies/ml) |
4.2 (3.7-4.5) |
4.2 (3.7-4.6) |
4.2 (3.9-4.4) |
| Years from diagnosis of HIVb |
1.3 (0.9-3.2) |
1.0 (0.7-4.0) |
1.6 (1.0-2.7) |
| HAART initiation since HIV+ (years)c |
3.6 (2.9-5.0) |
3.6 (3.2-5.4) |
3.5 (2.6-5.0) |
| HAART initiation since study entry (months)c | 22 (14–19) | 30 (28–31) | 17 (13–22) |
Data are expressed as median with interquartile range (IQR).
aEight individuals became anti-Tat Ab-positive during follow-up; bBased on 52 individuals.
cBased on data from 13 individuals, 4 anti-Tat Ab-positive with low and transient anti-Tat Abs (3 IgM and 1 IgG) and 9 anti-Tat Ab-negative.